<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Is Vertex Pharmaceuticals Stock Underperforming the S&amp;P 500? — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Is Vertex Pharmaceuticals Stock Underperforming the S&amp;P 500?</h2>
    <div class="badge">2025-09-08T12:35:30+00:00</div>
    <ul>
      <li>Moreover, its adjusted EPS of $4.52 surpassed the Street’s estimates by 6.6%.</li>
<li>4, Vertex Pharmaceuticals released its Q2 results, and its shares plummeted 20.6%.</li>
<li>Longer term, VRTX has plunged 1.6% on a YTD basis, lagging behind $SPX’s 10.2% rise.</li>
<li>Shares of REGN have declined 50.2% in the last 52 weeks and 19.5% on a YTD basis.</li>
<li>Driven by continued momentum, the company’s topline for the quarter surged 12.1% year-over-year to $2.96 billion, exceeding the consensus estimates by 2.6%.</li>
<li>More News from Barchart - CPI, S&amp;P 500 Additions and Other Key Things to Watch this Week - Analysts Keep Raising Shopify&#x27;s Targets - Make a 3.0% Yield in One-Month SHOP OTM Puts However, the biopharmaceutical titan has f</li>
<li>8, 2024.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Is Vertex Pharmaceuticals Stock Underperforming the S&amp;amp;P 500?\n• Moreover, its adjusted EPS of $4.52 surpassed the Street’s estimates by 6.6%.\n• 4, Vertex Pharmaceuticals released its Q2 results, and its shares plummeted 20.6%.\n• Longer term, VRTX has plunged 1.6% on a YTD basis, lagging behind $SPX’s 10.2% rise.\n• Shares of REGN have declined 50.2% in the last 52 weeks and 19.5% on a YTD basis.\n• Driven by continued momentum, the company’s topline for the quarter surged 12.1% year-over-year to $2.96 billion, exceeding the consensus estimates by 2.6%.\n• More News from Barchart - CPI, S&amp;P 500 Additions and Other Key Things to Watch this Week - Analysts Keep Raising Shopify&#x27;s Targets - Make a 3.0% Yield in One-Month SHOP OTM Puts However, the biopharmaceutical titan has f\n• 8, 2024." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/m/59379879-7a6a-342d-9125-5ff3f88c0168/is-vertex-pharmaceuticals.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>